Dr. Frankfurt on the Future of AML Treatments

Olga Frankfurt, MD
Published: Monday, Oct 30, 2017



Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.


Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x